--- abstract: 'Clozapine is an anti-psychotic used to treat refractory schizophrenia. This study reviews the rates of clozapine prescription for refractory schizophrenia in a region of Australia and compares the prescribing patterns to the estimated prevalence rates of refractory schizophrenia in the region. Utilising a pharmacoepidemiological approach; the results indicated that only 8.4% of the individuals estimated to be suffering from refractory schizophrenia in the region were prescribed clozapine between 2005 and 2010, with only 4.1% continuing clozapine to the conclusion of the study. In conclusion it is evident that clozapine is widely under-prescribed in this area of Australia.' altloc: - http://www.ojhas.org/issue41/2012-1-6.htm chapter: ~ commentary: ~ commref: ~ confdates: ~ conference: ~ confloc: ~ contact_email: ~ creators_id: - vella@uow.edu.au - ~ creators_name: - family: Vella given: SC honourific: '' lineage: '' - family: Pai given: NB honourific: '' lineage: '' date: 2012-04-15 date_type: published datestamp: 2013-05-04 23:04:38 department: ~ dir: disk0/00/00/88/71 edit_lock_since: ~ edit_lock_until: 0 edit_lock_user: ~ editors_id: - Kakkilaya BS editors_name: - family: Kakkilaya given: Srinivas honourific: Dr lineage: '' eprint_status: archive eprintid: 8871 fileinfo: /style/images/fileicons/application_pdf.png;/8871/1/2012-1-6.pdf full_text_status: public importid: ~ institution: ~ isbn: ~ ispublished: pub issn: ~ item_issues_comment: [] item_issues_count: ~ item_issues_description: [] item_issues_id: [] item_issues_reported_by: [] item_issues_resolved_by: [] item_issues_status: [] item_issues_timestamp: [] item_issues_type: [] keywords: Clozapine; Treatment-resistant schizophrenia; Prevalence rates; Australia lastmod: 2013-05-04 23:04:38 latitude: ~ longitude: ~ metadata_visibility: show note: ~ number: 1(6) pagerange: ~ pubdom: TRUE publication: Online Journal of Health and Allied Sciences publisher: BS Kakkilaya refereed: TRUE referencetext: "1.\tCapuano B, Crosby IT, Lloyd EJ. Schizophrenia: Genesis, receptorology, and current therapeutics. Current Medicinal Chemistry. 2002;9:521-548.\r\n2.\tConley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin. 1997;23(4):663-674.\r\n3.\tSemiz UB, cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2007;31:1330-1336. \r\n4.\tAngermyer MC, Loffler W, Muller P, Schulze B, Priebe S. Patients’ and relatives’ assessment of clozapine treatment. Psychological Medicine. 2001;31:509-517.\r\n5.\tWheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of Psychopharmacology. 2009;23(8):957-965.\r\n6.\tKelly DL, Kreyenbuhl J, Buchanan RW, Malhotra AK. Why not clozapine? Clinical Schizophrenia. 2007;1:92-95.\r\n7.\tHenneen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research 2005;73:139-145.\r\n8.\tYoung CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998;24(3): 381-390.\r\n9.\tReznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A. Myotoxicity and neurotoxicity during clozapine treatment. Clinical Neuropharmacology 2000;23(5):276-280.\r\n10.\tNielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists attitude towards and knowledge of schizophrenia treatment. Journal of Psychopharmacology. 2010;24(7):965-971.\r\n11.\tWheeler A, Humberstone V, Robinson G. Trends in anti-psychotic prescribing in schizophrenia in Auckland. Australasian Journal of Psychiatry 2006;14(2):169-174.\r\n12.\tMarder SR. Can clinical practice guide a research agenda? Schizophrenia Bulletin. 2002;28(1):127-129.\r\n13.\tConley RR, Kelly DL, Lambert TJ, Love RC. Comparison of clozapine use in Maryland and in Victoria Australia. Psychiatric Services. 2005;56(3):320-323.\r\n14.\tFayek M, Flowers C, Signorelli D, Simpson G. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatric Services. 2003;54(11):1453-1456.\r\n15.\tMond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry. 2002;37:55-61.\r\n16.\tWeinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2008;41:1-6. \r\n17.\tDrew LRH, Griffiths KM, Hodgson DM. A five year follow-up study of the use of clozapine in community practice. Australian and New Zealand Journal of Psychiatry 2002;36:780-786." relation_type: [] relation_uri: [] reportno: ~ rev_number: 10 series: ~ source: ~ status_changed: 2013-05-04 23:04:38 subjects: - JOURNALS - OJHAS succeeds: ~ suggestions: ~ sword_depositor: ~ sword_slug: ~ thesistype: ~ title: 'Prevalence & Prescription: Prescribing Practices of Clozapine in Australia between 2005 & 2010' type: journale userid: 4338 volume: 11